Anti-Human VEGF (Aflibercept Biosimilar)
Catalog #500004
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500004 | 1 mg | $400.00 | ||
| 500004 | 5 mg | $800.00 | ||
| 500004 | 20 mg | $1,600.00 |
Product Details
Aflibercept biosimilar is a recombinant fusion protein consisting of extracellular domains of vascular endothelial growth factor (VEGF) receptors 1 and 2, fused to the Fc portion of human IgG1. It acts as a VEGF trap, binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing their interaction with cellular VEGF receptors, thereby inhibiting abnormal angiogenesis and vascular permeability.
Specifications
| Clone | Aflibercept |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.2 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |